Citalopram is widely prescribed for anxiety disorders, even though its formal approval in most countries is for major depression rather than anxiety specifically. Several clinical trials have found it effective for generalized anxiety disorder, social anxiety disorder, and panic disorder, and prescribers commonly reach for it as an off-label option when anxiety is the primary concern. The evidence base is smaller than for some competing drugs, but it consistently points in a favorable direction, and the drug’s relatively clean side-effect profile has kept it popular for over two decades.
Why Citalopram Is Considered Off-Label for Anxiety
The U.S. Food and Drug Administration approved citalopram for major depressive disorder, not for any anxiety diagnosis. That means every prescription written specifically for generalized anxiety, social anxiety, or panic disorder is technically off-label. This is extremely common in psychiatry. A large study examining psychiatric prescribing patterns found that citalopram was one of the most frequently prescribed SSRIs outside its labeled indication, with a substantial share of its off-label use going toward mood and anxiety-related conditions.1PLOS ONE. Patterns and predictors of off-label prescription of psychiatric drugs “Off-label” does not mean unsupported or experimental; it simply means the manufacturer never pursued the costly regulatory process of getting approval for that specific diagnosis. Doctors rely on published evidence and clinical guidelines to justify these prescriptions, and for citalopram and anxiety, there is a reasonable body of both.
Escitalopram, the refined version of citalopram that contains only the pharmacologically active half of the molecule, does carry formal approvals for generalized anxiety disorder, social anxiety disorder, panic disorder, and obsessive-compulsive disorder in many countries.2PubMed. Escitalopram: a review of its use in the management of anxiety disorders Because escitalopram is essentially the purified active ingredient of citalopram, the anxiety benefits seen with escitalopram are often extrapolated back to its parent drug, and this reasoning has been part of why prescribers feel comfortable using citalopram for anxiety even without a matching label.
What the Clinical Evidence Actually Shows
The strongest anxiety-specific trial data for citalopram comes from studies of generalized anxiety disorder. In one open-label study, all thirteen patients treated with citalopram for twelve weeks showed full or partial improvement. Their average score on a standard anxiety rating scale dropped from about 22 to about 6, a steep decline that reflected meaningful gains in daily functioning.3PubMed. Treatment of generalized anxiety disorder with citalopram That study was small and lacked a placebo arm, but its results are consistent with broader SSRI evidence for GAD.
A placebo-controlled trial in older adults with late-life anxiety disorders found a clearer separation. Roughly two-thirds of participants on citalopram responded within eight weeks, compared with about a quarter of those on placebo.4PubMed. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial That response gap is sizable for a psychiatric medication and supports the idea that citalopram genuinely reduces anxiety rather than just improving mood in people who happen to feel anxious.
For panic disorder, a head-to-head comparison with fluoxetine found similar long-term efficacy between the two drugs, with high rates of sustained full remission. Fluoxetine appeared to work faster at lower doses, while citalopram needed a dose of around 30 mg per day to reach the same level of panic reduction.5Human Psychopharmacology: Clinical and Experimental. Short-term and long-term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram The fact that both SSRIs ended up at the same destination, even if they took different routes to get there, is reassuring.
Social anxiety disorder has also been studied. A twelve-week trial in patients who had both social anxiety and major depression found that about two-thirds responded on social anxiety measures and over three-quarters improved on depression measures. One notable finding was that social anxiety symptoms improved more slowly than depression, suggesting that people with social anxiety may need to stay on citalopram longer than the standard eight-to-twelve-week evaluation period before concluding it is not working.6PubMed. Citalopram treatment of social anxiety disorder with comorbid major depression Case reports have echoed this pattern, with authors noting that citalopram appeared effective for social anxiety and that these findings aligned with similar reports from other countries.7PubMed. Treatment of social anxiety disorder with citalopram
How Citalopram Reduces Anxiety
Citalopram works by blocking the reuptake of serotonin, a chemical messenger involved in mood regulation, fear processing, and stress response. By preventing serotonin from being quickly reabsorbed after it is released, the drug increases the amount available in the gaps between nerve cells.8PubMed Central. Long-Term Citalopram Treatment Alters the Stress Responses of the Cortical Dopamine and Noradrenaline Systems: the Role of Cortical 5-HT 1A Receptors Over weeks, this sustained increase in serotonin availability triggers downstream changes in how the brain’s receptors respond to stress signals. The anti-anxiety effect is not immediate because the brain needs time to adjust receptor sensitivity and recalibrate the circuits that generate fear and worry.
A comprehensive review described citalopram as benefiting patients with a range of conditions tied to serotonin dysfunction, including anxiety, panic disorder, obsessive-compulsive disorder, and premenstrual dysphoria.9PubMed. Citalopram: a comprehensive review This breadth of action makes sense given that serotonin pathways influence not just sadness or low mood but also the brain’s threat-detection system, which is overactive in most anxiety disorders.
The First Few Weeks Can Feel Worse Before Better
One of the most frustrating aspects of starting citalopram for anxiety is that it can temporarily increase anxious feelings during the first days or weeks. A study examining what happens after a single dose of citalopram in healthy volunteers found that the drug increased the processing of anxiety-related cues, essentially making people more attuned to fearful facial expressions and threatening stimuli.10PubMed. A single dose of citalopram increases fear recognition in healthy subjects The researchers suggested this mechanism could explain why SSRIs are known to worsen anxiety early in treatment.
This early jitteriness is not a sign the drug is wrong for you. Prescribers typically start at a low dose and increase gradually, partly to limit this initial spike. If you are already highly anxious, it helps to know that this phase usually passes within one to three weeks, and the longer-term trajectory is toward lower anxiety. Some doctors temporarily add a short-acting anti-anxiety medication during this startup window to bridge the gap.
How Citalopram Stacks Up Against Other SSRIs for Anxiety
One placebo-controlled trial directly compared citalopram with sertraline and found an interesting split. Both drugs outperformed placebo on depression measures, but on a dedicated anxiety rating scale, citalopram showed a statistically significant anxiety-reducing effect over placebo while sertraline did not.11PubMed. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline Sertraline also caused more gastrointestinal side effects and more early dropouts. This is one trial, so it would be a stretch to declare citalopram broadly superior. But it does suggest citalopram has legitimate anxiolytic properties that are not just a byproduct of treating underlying depression.
Escitalopram, which contains only the active S-enantiomer of citalopram, has been shown to achieve earlier and clearer separation from placebo than its parent drug, often at lower doses.12PubMed. Escitalopram: a review of its use in the management of major depressive and anxiety disorders In practical terms, if you and your doctor are choosing between citalopram and escitalopram for anxiety, escitalopram has more formal evidence and regulatory approval for anxiety diagnoses specifically. Citalopram may be chosen instead when cost matters (generic citalopram has been available longer and is sometimes cheaper) or when a patient has already responded well to it in the past.
Combining Citalopram with Therapy
Medication alone is rarely the whole story for anxiety. Research on combining SSRIs with cognitive behavioral therapy in young people with depression and anxiety found that the combination produced about 27% more improvement than medication alone by the twelve-week mark.13PubMed Central. Combining Selective Serotonin Reuptake Inhibitors and Cognitive Behavioral Therapy in Youth with Depression and Anxiety The study also revealed a timing pattern worth knowing about: the added benefit of therapy was not statistically detectable until around week twelve. In the early weeks, the SSRI did most of the heavy lifting. The therapy’s contribution accumulated more gradually, eventually pulling ahead of what the drug could do on its own.
For adults with anxiety, this pattern likely holds in some form. Citalopram can lower the baseline level of anxiety enough to make therapeutic techniques like exposure practice and cognitive restructuring feel manageable. The therapy, in turn, teaches skills that outlast the medication. If you stop taking citalopram at some point, having built those skills during treatment gives you tools the pill cannot leave behind.
Side Effects and the Dose Ceiling
Citalopram’s side-effect profile is considered relatively mild among SSRIs. Common complaints include nausea, dry mouth, drowsiness, and sexual side effects like reduced libido or difficulty reaching orgasm. These tend to be worst in the first couple of weeks and improve as the body adjusts.
The more serious safety conversation involves heart rhythm. The FDA issued a safety communication restricting citalopram’s maximum recommended dose to 40 mg per day (and 20 mg for people over 60) due to concerns about a heart rhythm abnormality called QTc prolongation. A study evaluating this risk found that QTc prolongation occurred in about 16% of patients after starting or increasing citalopram, and the rate rose with dose. Among patients aged 60 and older, about 22% showed prolongation.14PubMed Central. Physical Side Effects of Psychoactive Meds: Evaluation of QTc prolongation and dosage effect with citalopram The clinical significance of this finding remains debated, and the cardiac safety concern has been reinforced by analyses confirming that doses above 40 mg warrant caution.15PubMed. Cardiac safety concerns remain for citalopram at dosages above 40 mg/day
Interestingly, a large observational study found that patients on citalopram doses above 40 mg actually had lower risks of ventricular arrhythmia and all-cause mortality compared with those on lower doses, and no increased cardiac death risk was detected.16PubMed. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg This does not mean higher doses are safe for everyone; healthier patients may simply be the ones prescribed higher doses. But it does illustrate that the dose cap has been controversial, and some clinicians feel the FDA warning led to unnecessary treatment limitations for patients who needed and tolerated higher doses.
Older Adults Face Extra Considerations
The placebo-controlled trial mentioned earlier specifically enrolled older adults and demonstrated clear benefit for late-life anxiety.17PubMed. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial But older adults are also more vulnerable to a side effect called hyponatremia, a drop in blood sodium levels that can cause confusion, falls, and in severe cases, seizures. A population-based cohort study of older adults found that second-generation antidepressants (the class that includes citalopram) were associated with roughly a fivefold increase in the 30-day risk of hospitalization for hyponatremia compared with nonuse. The absolute risk was still low, roughly 0.3% versus 0.06%, but the relative jump is striking enough that doctors typically monitor sodium levels in older patients starting citalopram.18PubMed. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults
The lower maximum dose for people over 60 (20 mg rather than 40 mg) reflects both the QTc concerns and the fact that older adults metabolize the drug more slowly, leading to higher blood levels at any given dose. For anxiety specifically, 20 mg is often sufficient, but the ceiling can feel limiting if symptoms persist.
Genetics Affect How Much Drug You Actually Get
Citalopram is broken down in the liver primarily by an enzyme called CYP2C19, and people carry different genetic variants of that enzyme. A meta-analysis found that individuals who are poor metabolizers of CYP2C19 had roughly 95% higher exposure to citalopram compared with normal metabolizers, meaning the drug lingers much longer at higher concentrations in their blood. On the other end, ultrarapid metabolizers cleared the drug about 36% faster, potentially leaving them with too little active drug to achieve a therapeutic effect.19PubMed. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis
In practice, this means two people on the same dose of citalopram can have dramatically different drug levels. If you are a poor metabolizer, a standard 20 mg dose might feel like 40 mg in terms of both benefit and side effects. If you are an ultrarapid metabolizer, the same dose may feel underwhelming. Pharmacogenomic testing, increasingly available through simple cheek-swab kits, can identify your CYP2C19 status. This is especially useful if you have tried citalopram and found it either intolerable at low doses or ineffective at standard ones.
Stopping Citalopram Requires a Gradual Taper
Discontinuation symptoms are a real and underappreciated issue with SSRIs, and citalopram is no exception. Abruptly stopping the medication can produce dizziness, electric-shock sensations (sometimes called “brain zaps”), irritability, nausea, and a rebound in anxiety that can be mistaken for a relapse. Standard guidelines have historically recommended tapers of two to four weeks, but research suggests these short tapers often provide minimal benefit over stopping cold and are frequently poorly tolerated. A more recent analysis of serotonin transporter imaging data proposed that SSRIs should be tapered much more slowly, over months rather than weeks, reducing the dose in progressively smaller steps. This approach, sometimes called a hyperbolic taper, matches the way the drug’s effect on serotonin transporters actually scales with dose and appears to minimize withdrawal symptoms more effectively.20The Lancet Psychiatry. Tapering of SSRI treatment to minimise discontinuation syndrome
If you and your doctor decide citalopram has served its purpose and you want to come off, plan for a gradual process. Liquid formulations or pill-splitting can help achieve the very small dose reductions recommended in the later stages of tapering. Rushing this step is one of the most common reasons people end up back on the medication, not because they needed it for anxiety but because the withdrawal symptoms convinced them their anxiety was returning.
Pregnancy and Citalopram
For people who become pregnant while taking citalopram, the safety picture is cautiously reassuring. A prospective controlled study found that citalopram use during the period when organs are forming was not associated with an apparent increase in major birth defects. However, use later in pregnancy was linked to a higher risk of neonatal adaptation syndrome, a cluster of short-lived symptoms in the newborn such as jitteriness, feeding difficulty, and respiratory distress.21American Journal of Obstetrics & Gynecology. Pregnancy outcome following citalopram use during pregnancy: A prospective controlled study These symptoms are generally mild and self-limiting, but they can be alarming to new parents who are not expecting them. Untreated severe anxiety during pregnancy carries its own risks, including preterm birth and low birth weight, so the decision to continue or stop citalopram during pregnancy is one that requires weighing specific individual circumstances rather than following a blanket rule.